Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real-World Retrospective Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10503155" target="_blank" >RIV/00179906:_____/25:10503155 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/25:A2603DK7 RIV/00216208:11110/25:10503155 RIV/00216208:11120/25:43928851 RIV/00216208:11130/25:10503155 and 10 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Kor_Lt9P-t" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Kor_Lt9P-t</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/dth/5548750" target="_blank" >10.1155/dth/5548750</a>
Alternative languages
Result language
angličtina
Original language name
Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real-World Retrospective Study
Original language description
Introduction: Janus kinase (JAK) inhibitors are novel therapies for atopic dermatitis (AD); however, only limited data exist on their effectiveness in patients with previous failures in biological treatment. Methods: Patients with moderate-to-severe AD and having completed a minimum of 16 weeks of JAK inhibitor therapy were divided into subgroups based on prior dupilumab exposure: those without prior exposure and those whose treatment was discontinued due to lack of efficacy (dupilumab nonresponders [DNR]). Eczema Area and Severity Index (EASI), DLQI, and Itch Numeric Rating Scale (Itch NRS) changes from baseline were assessed in Weeks 16 and 24 (when available). Adverse events during the follow-up were recorded. Results: In total, 241 patients were included; 148 received upadacitinib (99 dupilumab-naïve, 49 post-dupilumab failure), 47 were with baricitinib (32 dupilumab-naïve, 15 post-dupilumab failure), and 46 received abrocitinib (35 dupilumab-naïve, 11 post-dupilumab failure). At Week 16, an EASI-75 response in the upadacitinib group was achieved in 86% naïve versus 82% DNR patients, 91% naïve versus 73% DNR patients in the abrocitinib group, and 81% naïve versus 67% DNR in the baricitinib group. Itch NRS GREATER-THAN OR EQUAL TO 4-point reduction was achieved in 82% naïve versus 76% DNR patients on upadacitinib, 83% naïve versus 91% DNR patients on abrocitinib, and 72% naïve versus 40% DNR patients on baricitinib. Conclusion: In conclusion, our retrospective analysis suggests that previous dupilumab failure did not significantly affect the short-term effectiveness of JAK inhibitor therapy for AD.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Dermatologic Therapy
ISSN
1396-0296
e-ISSN
1529-8019
Volume of the periodical
2025
Issue of the periodical within the volume
September
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
5548750
UT code for WoS article
001575215100001
EID of the result in the Scopus database
2-s2.0-105016820079